Navigation Links
Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Date:8/27/2007

First patient treated in trial of prGCD treatment of Gaucher Disease

CARMIEL, Israel, Aug. 27 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: PLX), today announced that it has treated the first patient in its phase III clinical trial of the Company's lead product candidate, prGCD, a proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD) for the treatment of Gaucher disease, a lysosomal storage disorder in humans.

The phase III clinical trial will take place in centers in the United States, Israel and other locations worldwide. Professor Ari Zimran, Director of the Gaucher Clinic at Shaare Zedek Medical Center in Jerusalem, Israel, will serve as principal investigator for the trial. The trial design consists of 30 male and female patients with Gaucher disease in a randomized, double- blind, dose ranging study, with two parallel groups.

Dr. David Aviezer, President and CEO of Protalix, stated, "Enrolling our first patients in this phase III clinical trial represents a significant milestone as we work toward our goal of commercializing prGCD, our proprietary treatment for Gaucher disease. After extensive research from the committed members of our team, we believe that we have developed a treatment that will not only be effective, but also safe and cost efficient when compared to current treatment options. We look forward to monitoring the progress of our trial and the potential benefits for our participating patients."

Professor Ari Zimran added, "With the treatment of the first patient in the phase III clinical trial, we are one step closer to providing another treatment option for those who suffer from Gaucher disease. Progress to date has been very e
'/>"/>

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
2. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
3. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
4. Newest Adult Stem Therapy Treats Diabetes
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
9. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
10. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
11. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2008)...-- Alpharma Inc. (NYSE: ALO ),a global specialty...rom,clinical trials that showed ALO-01 (EMBEDA(TM)...red naltrexone hydrochloride) capsules,demonstrate...ability,alongside a promising safety and efficacy ...the 27th Annual Scientific Session of the American...
(Date:5/8/2008)...Therapeutic Proteins at Tumor,Site, ARLINGTON H...ng gene,therapy, plastic surgeons have delivered c...on cancerous tumors on rats with a 79 percent redu... May issue of Plastic and,Reconstructive Surgery(R...ciety of Plastic Surgeons (ASPS). This new deliver...
(Date:5/8/2008)...of the American Pain Society ... -- Patients treated with lacosamide,demonstrated ...in (DNP),compared to placebo-treated patients, ac...ng of the American Pain Society (APS) in Tampa, Fl...f a diabetic neuropathic,pain treatment providing ...
(Date:5/8/2008)...estigators to Assess BSI-201 Therapy in ..., Calif., May 8 /- BiPar Sciences, In...al trial programs for its lead,product, BSI-201, i... trial,of BSI-201 that BiPar has launched in the p...st and brain cancer., The company is evaluating B...
Breaking Medicine Technology:Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 2Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 3Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 4Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 5Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 6Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 7Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 2Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 3New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 2New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 3New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 4BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer 2Indevus Announces Allergan as New Partner for SANCTURA Brand 674 1Indevus Announces Allergan as New Partner for SANCTURA Brand 674 2Indevus Announces Allergan as New Partner for SANCTURA Brand 674 3Indevus Announces Allergan as New Partner for SANCTURA Brand 674 4Indevus Announces Allergan as New Partner for SANCTURA Brand 674 5Indevus Announces Allergan as New Partner for SANCTURA Brand 674 6ACTOS 28R 29 28pioglitazone HCl 29 Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes 314 1ACTOS 28R 29 28pioglitazone HCl 29 Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes 314 2ACTOS 28R 29 28pioglitazone HCl 29 Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes 314 3Clarient to Present at the UBS 2007 Global Life Sciences Conference 1554 1Clarient to Present at the UBS 2007 Global Life Sciences Conference 1554 2MAKO Surgical Corp Files Registration Statement for Initial Public Offering of Common Stock 670 1MAKO Surgical Corp Files Registration Statement for Initial Public Offering of Common Stock 670 2
...DA, Md., March 20, 2007--Researchers studying infl...here and in tropical,areas, specifically Brazil, u...nfluenza travels from low populated regions near t...rk, funded by the,Fogarty International Center (NI...), can improve planning for influenza control in,t...
...ust Remain on the Millions Still Suffering from Ch.../PRNewswire/ -- The Centers for Disease,Control an...ecline,in the rates of new acute hepatitis infecti...lecting the success of hepatitis A and B,vaccinati...o,highlight these positive results, but remind peo...
Other Medicine Technology:Researchers Find Surprising Pattern of Influenza Spread in South,America and Tropics 2Researchers Find Surprising Pattern of Influenza Spread in South,America and Tropics 3The American Liver Foundation Urges Cautious Optimism about CDC,Report on Declining Acute Hepatitis Infection Rates 2The American Liver Foundation Urges Cautious Optimism about CDC,Report on Declining Acute Hepatitis Infection Rates 3
(Date:5/12/2008)...irstCall/ -- NBTY, Inc. (NYSE:,NTY) (http://www.N...ter of,nutritional supplements, today announced th...s for the month of April 2008 by segment:, , ... (Preliminary and Unaudited) ... ($ In Millions), ...
(Date:5/12/2008)...May 12, 08:30 a.m. EDT at ...ay 12 /PRNewswire-FirstCall/ -- Isis,Pharmaceutica...ncial results,for the quarter ended March 31, 2008...a net operating loss (NOL) of $5.1 million, exclud... compared to a pro forma NOL,of $18.5 million in t...
(Date:5/12/2008)...FirstCall/ -- Cepheid (Nasdaq:,CPHD) today announc...Premier, Inc., one of the largest U.S. Group Purch...rticipating hospitals and 42,000 other,healthcare ... has also,signed a preferred vendor agreement with..., a collaboration of 53 acute care hospitals that ...
(Date:5/12/2008)...all/ - Innolife Pharma, Inc.,(Other OTC:INNP.PK - ...ht,months regarding the formation of a joint ventu...negotiations where final written terms have been,s... Company,s very first,product acquisition. It shou... over this extended period due to the successful, ...
Breaking Medicine News(10 mins):Health News:NBTY Announces Preliminary Unaudited Net Sales Results for April 2008 2Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 2Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 3Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 4Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 5Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 6Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 7Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 8Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 9Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 10Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 11Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 12Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 13Health News:Isis Reports Financial Results and Highlights for First Quarter of 2008 14Health News:Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations 2Health News:Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations 3Health News:Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations 4Health News:Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture 2
...diagnose localised prostate cancer, one of the mor...e than previously believed, researchers at Sweden'...d concentrations of prostate-specific antigen (PSA...atients and monitored the development of the disea...
...ast-feeding can negate the risks of breast cancer ...egnancies, after the age of 25. The findings of t...nday, April 16 at the 2007 annual meeting of the A...r Research held in Los Angeles. "Breastfeeding ma...
Hotdogs And Co.-The Long And Short Of It
...rchers, a smoking ban which began March 2004, has ...astic cut //in air pollution, the health of bar wo...gures, the researchers gave an 83 percent reductio...t in cancer-causing agents. In addition, the repo...
Other Medicine News:Health News:Method to Screen Prostate Cancer Less Effective 2Health News:Breastfeeding Keeps Breast Cancer At Bay- For Older Mothers 2Health News:Hotdogs And Co.-The Long And Short Of It 2Health News:Ireland’s Smoke Ban Seems To Do The Tric 2
The HEMOCHRON Model 401 is a portable, single-well whole blood coagulation monitoring instrument. The 401 provides on-screen plasma equivalent PT and APTT test results.
The fat loss formula's key ingredient of 2.0% aminophylline works by penetrating deep into the skin where it causes the body fat cells to shrink, resulting in up to 2 inches of body fat loss.
A device combining the "palpate & roll technique to vacuum massage, innovation dedicated to efficiency.
...ople, you must understand the patients you care fo...ng population, your patients may need assistance i...nch low height, the Ritter 222 Barrier-Free Exam T...e the elderly, expectant mothers or patients with ...
Medicine Products: